{"a": [["Acarbose and secondary prevention after coronary stenting", "2018"], ["Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study", "2006"], ["Standards of medical care for patients with diabetes mellitus", "2003"], ["Diagnosis and classification of diabetes mellitus", "2010"], ["Strategies for effective screening, intervention and follow\u2010up", "2014"], ["Standards of medical care in diabetes\u20102015", "2015"], ["Cardiovascular disease risk profiles", "1991"], ["Designing psycho\u2010oncology randomised trials and cluster randomised trials: variance components and intra\u2010cluster correlation of commonly used psychosocial measures", "2013"], ["Basics of meta\u2010analysis: I\u00b2 is not an absolute measure of heterogeneity", "2017"], ["Prediction intervals", "2017"], ["Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial", "2014"], ["Long\u2010term studies of treatments for type 2 diabetes", "2016"], ["2014 National Diabetes Statistics Report", "2015"], ["The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance", "1996"], ["Weight gain as a risk factor for clinical diabetes mellitus in women", "1995"], ["Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool", "2014"], ["Chapter 9: Analysing data and undertaking meta\u2010analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017", "2017"], ["Fasting hyperglycemia in non\u2010insulin\u2010dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake", "1989"], ["Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", "2002"], ["10\u2010year follow\u2010up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study", "2009"], ["Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta\u2010analysis", "2014"], ["Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance", "2001"], ["Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice", "2014"], ["GRADEpro GDT", "2015"], ["Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus", "2016"], ["Sodium\u2010glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus", "2016"], ["Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus", "2017"], ["Dipeptidyl\u2010peptidase (DPP)\u20104 inhibitors and glucagon\u2010like peptide (GLP)\u20101 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus", "2017"], ["Quantifying heterogeneity in a meta\u2010analysis", "2002"], ["Measuring inconsistency in meta\u2010analysis", "2003"], ["A re\u2010evaluation of random\u2010effects meta\u2010analysis", "2009"], ["Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017", "2017"], ["Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta\u2010analysis of randomised controlled clinical trials", "2011"], ["Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors", "2013"], ["International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR &amp; ICH Guidelines", "1997"], ["IDF Diabetes Atlas", "2017"], ["International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes", "2009"], ["The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC\u2010InterAct study", "2013"], ["Low\u2010dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity", "1993"], ["Beta\u2010cell function is a major contributor to oral glucose tolerance in high\u2010risk relatives of four ethnic groups in the U.S", "2002"], ["Does suppression of postprandial blood glucose excursions by the alpha\u2010glucosidase inhibitor miglitol improve insulin sensitivity in diet\u2010treated type II diabetic patients?", "2006"], ["Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP\u2010NIDDM data", "2004"], ["The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews", "2010"], ["Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program", "2006"], ["Hyperglycemia and cardiovascular disease in type 2 diabetes", "1999"], ["The PRISMA statement for reporting systematic and meta\u2010analyses of studies that evaluate interventions: explanation and elaboration", "2009"], ["Comparison of registered and published primary outcomes in randomized controlled trials", "2009"], ["Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non\u2010insulin\u2010treated NIDDM patients", "1998"], ["A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation", "2014"], ["Parental transmission of type 2 diabetes: the Framingham Offspring Study", "2000"], ["Effect of acarbose on insulin sensitivity in elderly patients with diabetes", "2000"], ["Progression rates from HbA1c 6.0\u20106.4% and other prediabetes definitions to type 2 diabetes: a meta\u2010analysis", "2013"], ["Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999\u20102006", "2011"], ["Efficacy of acarbose in Chinese subjects with impaired glucose tolerance", "2003"], ["Cost\u2010effectiveness of acarbose for the management of impaired glucose tolerance in Sweden", "2005"], ["Review Manager 5 (RevMan 5)", "2014"], ["Interpretation of random effects meta\u2010analyses", "2011"], ["Response to Chiasson et al.: acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP\u2010NIDDM Trial data", "2004"], ["Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017", "2017"], ["Racial differences in glycemic markers: a cross\u2010sectional analysis of community\u2010based data", "2011"], ["Improvement of insulin sensitivity and dyslipidemia with a new alpha\u2010glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects", "1996"], ["Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?", "2002"], ["Recommendations for examining and interpreting funnel plot asymmetry in meta\u2010analyses of randomised controlled trials", "2011"], ["Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta\u2010analysis of lifestyle, pharmacological and surgical interventions", "2015"], ["Type 2 diabetes: principles of pathogenesis and therapy", "2005"], ["Prediabetes: a high\u2010risk state for diabetes development", "2012"], ["Intensive glucose control and macrovascular outcomes in type 2 diabetes", "2009"], ["Alpha\u2010glucosidase inhibitors for type 2 diabetes mellitus", "2005"], ["Technical Report Series No. 727. Report of a WHO Study Group", "1985"], ["Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation", "1998"], ["Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation", "2006"], ["Comparison of top\u2010performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and Embase", "2006"], ["Developing optimal search strategies for detecting clinically sound treatment studies in Embase", "2006"], ["Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta\u2010epidemiological study", "2008"], ["The epidemic of pre\u2010diabetes: the medicine and the politics", "2014"]], "ex": [["Prevention of postprandial hyperglycemia by acarbose may be a promising therapeutic strategy for reducing the increased risk for cardiovascular disease (ABDOMEN)", "2018"], ["Effect of miglitol and sitagliptin on incretin levels", "2010"], ["HbA1c measurement improves the detection of type 2 diabetes in high\u2010risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP)", "2001"], ["A randomized comparative clinical study on suppression of progression from early diabetes, diet/exercise standard intervention vs. concurrent pharmacological standard intervention", "2018"], ["Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early\u2010stage diabetic patients", "2012"], ["Effects of acarbose in patients with beta\u2010thalassaemia major and abnormal glucose homeostasis", "2004"], ["A double\u2010blind, randomised placebo controlled study of the effects of acarbose on endothelial function, hemostatic and fibrinolytic plasmatic factors in patients with stable coronary artery disease and either impaired glucose intolerance or newly diagnosed diabetes mellitus", "2004"], ["Three\u2010arm comparative study of miglitol and mitiglinide alone and in combination \u2010efficacy and safety studies", "2031"], ["The comparative study of the effects of miglitol and voglibose (alpha\u2010glucosidase inhibitors) on incretins secretion", "2009"], ["Additional glucose lowering and anti\u2010inflammatory effects by acarbose and alcohol in subjects with impaired glucose tolerance or mild type 2 diabetes", "2018"], ["Study of the combination use effect of DPP\u20104 inhibitor and alpha\u2010glucosidase inhibitor", "2012"], ["Linagliptin study of effects on PPG, postprandial blood glucose control", "2012"], ["The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3\u2010year multicenter prospective study [Chinese translation from Bayer website www.stop\u2010niddm.com, accessed 13 September 2004, no longer available]", "2001"]], "in": [["Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction?", "2017"], ["Acarbose cardiovascular evaluation", "2014"], ["Dutch acarbose intervention trial (DAISI)", "2008"], ["Possible prevention of type 2 diabetes with acarbose or metformin over three years", "2000"], ["Effect of medicine and non\u2010medicine intervention on the outcomes of patients with impaired glucose tolerance: 5\u2010year follow\u2010up", "2004"], ["Voglibose for prevention of type 2 diabetes mellitus: a randomised, double\u2010blind trial in Japanese individuals with impaired glucose tolerance", "2009"], ["Impact of acarbose on carotid intima\u2010media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one\u2010year, prospective, randomized, open\u2010label, parallel\u2010group study in Japanese adults with established coronary artery disease", "2010"], ["The &quot;STOP NIDDM&quot; program \u2010 can diabetes in the aged be prevented? An international long\u2010term study revisited; does acarbose delay or prevent the manifestations of type II diabetes", "1997"], ["An evalualion on efficacy of acarbose interfering trentment on IGT", "2000"], ["Effect of acarbose on long\u2010term prognosis in acute coronary syndromes patients with newly diagnosed impaired glucose tolerance", "2016"]]}